iTeos Therapeutics outlined business updates and strategic priorities for 2024. Program Highlights: Belrestotug: IgG1 anti-TIGIT monoclonal antibody targeting first-line non-small cell lung cancer and head and neck squamous cell carcinoma in collaboration with GSK; Preparation underway for Phase 3 registrational studies that will evaluate the belrestotug + dostarlimab doublet; GALAXIES Lung-201: topline data from Phase 2 platform trial assessing belrestotug + dostarlimab doublet in first-line advanced/metastatic non-small cell lung cancer anticipated in 2024; GALAXIES H&N-202: enrollment ongoing in Phase 2 platform study assessing belrestotug + dostarlimab doublet and a triplet with GSK’s investigational anti-CD96 antibody in first-line patients with PD-L1 positive recurrent / metastatic HNSCC; TIG-006 HNSCC: topline data from Phase 2 expansion trial assessing belrestotug + dostarlimab doublet in first-line PD-L1 positive advanced or metastatic HNSCC anticipated in 2024; TIG-006 mNSCLC: enrollment ongoing in Phase 2 expansion trial assessing belrestotug, dostarlimab, and chemotherapy triplet in first-line advanced or metastatic NSCLC; TIG-007: the Company has deprioritized the Phase 1/2 TIG-007 trial assessing belrestotug and in combination with Bristol Myers Squibb’s iberdomide due to the evolving treatment landscape in relapsed/refractory multiple myeloma; Continued advancement of Phase 1b trials exploring two novel triplets in advanced solid tumors: belrestotug + dostarlimab and GSK’s investigational anti-CD96 antibody (GSK’608), and belrestotug + dostarlimab and GSK’s investigational anti-PVRIG antibody. Adenosine Pathway: Inupadenant: insurmountable small molecule antagonist targeting adenosine A2A receptor in second-line NSCLC; A2A-005: topline data from the dose escalation portion of the Phase 2 trial with inupadenant and platinum-doublet chemotherapy in post-IO metastatic non-squamous NSCLC anticipated in late 2024; IO-001: completed enrollment of the Phase 2 IO-001 monotherapy high biomarker trial in advanced solid tumors. The Company plans to integrate IO-001 biomarker knowledge into the development strategy of future inupadenant clinical trials. EOS-984: first-in-class small molecule targeting equilibrative nucleoside transporter 1, a dominant transporter of adenosine on lymphocytes involved in T cell metabolism, expansion, effector function, and survival; Preclinical mechanism of action data anticipated in the second quarter of 2024; Topline data from the Phase 1 dose escalation trial in advanced malignancies anticipated in the second half of 2024. The Company’s cash and cash equivalent position was $644.9 million as of September 30, 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ITOS:
